Ventyx Biosciences Inc (VTYX) Quote

This will be taking off again tomorrow.

This will be taking off again tomorrow.

Keep in mind they are also selling 100 million Shares or 300 million Dollars' worth of securities:

The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus other than the shares under the sales agreement will be specified in a prospectus supplement to the base prospectus. The specific terms of the securities to be issued and sold under the sales agreement are specified in the sales agreement prospectus that immediately follows the base prospectus. The $100,000,025 of common stock that may be offered, issued and sold under the sales agreement prospectus is included in the $300.0 million of securities that may be offered, issued and sold by us under the base prospectus. If the sales agreement with Jefferies LLC is terminated, any portion of the $100,000,025 of common stock included in the sales agreement prospectus that is not sold pursuant to the sales agreement will become available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement, and if no shares are sold under the sales agreement, the full $100,000,025 of securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement.


https://www.otcmarkets.com/filing/html?id=17263201&guid=o0d-kFHS95BWJth

VTYX: Yep!! Several days ago now, I posted 3-times to that board specifically to call that clown "JobyNimble" --- Orion's official CENSOR --- every disparaging epithet known to mankind!!!

PS: I'm doing VERY well today on @EBS.

$MEDS the stock are you really banned on ORIONS board

VTYX: I am BANNED from the Orion's board, so I could NOT reply to your inquiry from there, to wit, "DID YOU TAKE YOUR MEDS THIS MORNING?" In any event, YES I did, Bro!!! A spoon full of LSD!!! And boy, I just HATE when this happens!!!!!

VTYX: And THAT's how ya do it, Boss!!! CONGRATS!!!

MISSED THE 4.80 DIP


ARGGGGG

BACK IN 5.81 AFTER SELLING 7.07

VTYX: "Hey, Rocky!! Watch me pull a rabbit out of my HAT!!!" ("AGAIN??")

$VTYX VTYX - $VTYX

Piper and Jefferies saying Ventyx Bio. (VTYX) might be the next big weight loss drug citing a new publication showing NLRP3 has significant weight loss similar to GLP-1. ---------------------------
New published industry data suggests NLRP3 inhibition in the CNS…— Marc Lehman (@markflowchatter) February 21, 2024

Well it took awhile to hit,but much better than I expected.

VTYX: Winner of this day????? (Hmmm)

Nothing buy BAD news for MONTHS about this Firm --- trashed studies, etc. --- but TODAY will likely hit Jupiter within 20-minutes from liftoff!!

4 insiders exercised option buys at 2.49 for a total of 530K shares.
I’m in.

Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference
November 21 2023 - 04:05PM

Alert
Print
Share On Facebook

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming 35th Annual Piper Sandler Healthcare Conference.
Event: 35th Annual Piper Sandler Healthcare Conference
Location: New York, NY
Date: Tuesday, November 28, 2023
Time: 1:30-1:55 PM ET
A webcast of the presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event for thirty days.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in San Diego, California. For more information about Ventyx, please visit www.ventyxbio.com.

Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com

Looking good

That would teach the shorts a valuable lesson!

The shorts got a Fu'ken Death Grip on this! It looks like they may lose control of the stock today if this can break above 2.80 it's game on!!

Will ad more this week

Looks like a play in this one

Right now I am playing December and March call options. With these prices at $2.40 I am thinking about actually buying the stock.

The prices are insanely cheap right now with them having 300 million in cash.

This stock should be at $15pps!

Everything looks good to go here. I am not sure why this was taken down from $15 to $2.50 on just one of their pipeline drugs being pulled by the company in order to save their cash burn rate?

They still have four other drugs in the pipeline here.

With $300 million in cash this will get them all the way through 2025.

I believe this selloff was an overreaction and a very nice bounce is in order here.

Ventyx Biosciences Reports Third Quarter 2023 Financial Results and
Highlights Recent Corporate Progress


Ventyx to provide updates across clinical-stage portfolio in the
first quarter of 2024


Cash, cash equivalents and marketable securities of $300.8 million
as of September 30, 2023


SAN DIEGO, November 9, 2023 (GLOBE NEWSWIRE) – Ventyx Biosciences,
Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical
company focused on advancing novel oral therapies that address a
broad range of inflammatory diseases with significant unmet medical
need, today announced financial results for the third quarter ended
September 30, 2023, and highlighted recent pipeline and business
progress.


“We are committed to progressing our wholly-owned portfolio of
novel small molecule drug candidates,” said Raju Mohan, Chief
Executive Officer. “We look forward to providing important pipeline
updates in the first quarter of 2024, including the VTX958 Phase 2
Crohn’s disease interim efficacy analysis, an update from the
open-label extension of the VTX002 Phase 2 trial in ulcerative
colitis, Phase 2 data for our peripheral NLRP3 inhibitor, VTX2735,
in CAPS, and Phase 1 data for our novel CNS penetrant NLRP3
inhibitor, VTX3232, in healthy volunteers.”


Pipeline Updates


▪

VTX958 (TYK2 Inhibitor):
We recently announced topline results from the Phase 2 trial of
VTX958 in plaque psoriasis. While the trial met its primary and
secondary endpoints, the efficacy results did not meet our internal
target to support further development of VTX958 in psoriasis.
Accordingly, we have elected to terminate ongoing activities in the
Phase 2 trials of VTX958 in plaque psoriasis and psoriatic
arthritis. The ongoing Phase 2 trial of VTX958 in Crohn’s disease
will continue with the addition of an interim efficacy analysis to
be conducted in the first quarter of 2024.

▪

VTX002 (S1P1R Modulator):
In October 2023, we announced positive results from the Phase 2
trial of VTX002 in patients with moderately to severely active
ulcerative colitis (UC). We believe these data establish VTX002 as
a potential best-in-disease oral agent in UC based on its
differentiated efficacy profile, including a high rate of complete
endoscopic remission, and its potential best-in-class safety
profile. Phase 3 planning activities are underway. We expect to
provide an update from the open-label extension of the Phase 2
trial in ulcerative colitis trial during the first quarter of
2024.

▪

VTX2735 (Peripheral NLRP3 Inhibitor):
We are conducting a Phase 2 trial of VTX2735 in patients with
familial cold autoinflammatory syndrome (FCAS). FCAS is the most
common subset of cryopyrin-associated periodic syndrome (CAPS), a
group of rare autoinflammatory conditions caused by
gain-of-function mutations in the NLRP3 gene. Patient enrollment is
progressing, and we expect to provide an update on the trial in the
first quarter of 2024. In addition to CAPS, we believe systemic
NLRP3 inhibition with VTX2735 may have therapeutic potential across
a broad range of chronic inflammatory conditions that are
characterized by NLRP3-induced excess IL-1ß, including
dermatologic, rheumatic and cardiovascular diseases.

▪

VTX3232 (CNS-penetrant NLRP3 Inhibitor):
We are conducting a Phase 1 trial of VTX3232 in adult healthy
volunteers. The trial is designed to characterize the safety,
pharmacokinetics and pharmacodynamics of VTX3232 in blood, and will
also measure drug concentration and target engagement in the
cerebral spinal fluid. We believe that the profile of VTX3232 may
establish it as a compelling therapeutic for a range of
neuroinflammatory conditions with high unmet medical need,
including Parkinson’s disease, multiple sclerosis, Alzheimer’s
disease and amyotrophic lateral sclerosis, among others. We expect
to provide an update on the Phase 1 trial of VTX3232 in the first
quarter of 2024.

Third Quarter 2023 Financial Results


▪

Cash Position:
Cash, cash equivalents and marketable securities were $300.8
million as of September 30, 2023.

▪

Research
and Development (R&D) expenses:
R&D expenses were $49.8 million for the quarter ended September
30, 2023, compared to $25.5 million for the quarter ended September
30, 2022.

▪

General and Administrative (G&A) expenses:
G&A expenses were $8.2 million for the quarter ended September
30, 2023, compared to $6.0 million for the quarter ended September
30, 2023.

1





▪

Net loss:
Net loss was $54.0 million for the quarter ended September 30,
2023, compared to $30.5 million for the quarter ended September 30,
2022.

About Ventyx Biosciences


Ventyx is a clinical-stage biopharmaceutical company focused on
developing innovative oral medicines for patients living with
autoimmune and inflammatory disorders. We believe our ability to
efficiently discover and develop differentiated drug candidates
will allow us to address important unmet medical need with novel
oral therapies that can shift immunology markets from injectable to
oral drugs. Our current pipeline includes internally discovered
clinical programs targeting TYK2, S1P1R and NLRP3, positioning us
to become a leader in the development of oral immunology therapies.
Ventyx is headquartered in San Diego, California. For more
information about Ventyx, please visit
www.ventyxbio.com.


Forward-Looking Statements


Ventyx cautions you that statements contained in this press release
regarding matters that are not historical facts are forward-looking
statements. These statements are based on Ventyx’s current beliefs
and expectations. Such forward-looking statements include, but are
not limited to, statements regarding: the potential of Ventyx’s
product candidates and the anticipated continued progression of the
development pipeline for such product candidates; the anticipated
continuance of the Phase 2 trial of VTX958 in Crohn's disease; the
therapeutic and commercial potential of VTX002 in ulcerative
colitis, including its potential as a best-in-disease oral agent
and its potential best-in-class safety profile; and the anticipated
timing of updates regarding the VTX958 Phase 2 trial in Crohn's
disease, the VTX3232 Phase 1 trial, the VTX2735 Phase 2 trial in
CAPS, and the open-label extension of the VTX002 Phase 2 trial. The
inclusion of forward-looking statements should not be regarded as a
representation by Ventyx that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Ventyx’s
business, including, without limitation: potential delays in the
commencement, enrollment and completion of clinical trials;
Ventyx’s dependence on third parties in connection with product
manufacturing, research and preclinical and clinical testing;
disruptions in the supply chain, including raw materials needed for
manufacturing and animals used in research, delays in site
activations and enrollment of clinical trials; the results of
preclinical studies; early clinical trials not necessarily being
predictive of future results; interim results not necessarily being
predictive of final results; the potential of one or more outcomes
to materially change as a trial continues and more patient data
become available and following more comprehensive audit and
verification procedures; regulatory developments in the United
States and foreign countries; unexpected adverse side effects or
inadequate efficacy of Ventyx’s product candidates that may limit
their development, regulatory approval and/or commercialization, or
may result in recalls or product liability claims; Ventyx’s ability
to obtain and maintain intellectual property protection for its
product candidates; the use of capital resources by Ventyx sooner
than expected; disruption to Ventyx’s operations from the ongoing
military conflicts in Ukraine and the Middle East, including
clinical trial delays; and other risks described in Ventyx’s prior
press releases and Ventyx’s filings with the Securities and
Exchange Commission (SEC), including in Part II, Item 1A (Risk
Factors) of Ventyx’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2023, filed on or about November 9, 2023, and
any subsequent filings with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and Ventyx undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.


Investor Relations Contact


Patti Bank

Managing Director

ICR Westwicke

(415) 513-1284
IR@ventyxbio.com

300 million in cash trading at a 50% discount! Not for long shorts! You are all going to get your nuts caught!

Looking forward to earning as I believe we will see $6 on the cash alone. This is extremely oversold!

Accumulation today looks better but chart is testing a break down

Grabbed a few thousand

Yeah 4 5 should be in play sooner than later . 80% drop is massive

Yep that’s a strange one. Something else is cooking I’m assuming. Anyway not selling any shares until we see 5. Plus which is right around the corner

The efficacy results were good JUST not good enough for the company - seems rather strange that the company wouldn't accept the passing grade and rather sabotage the trials because they wanted better results than the acceptable results.

I’m in

Got in 2.60 Will see over réactions imo

I Bought some Dec 15th 2.50 calls. The company still has over 300 million in cash. I think this selloff was a major overreaction.

Let's see how it does going into earnings on Nov 13th?

VTYX. Some bios are very risky.

RIP

mb

VTYX—(-79%/AH)—terminates VTX958 psoriasis and PsA programs following phase-2 readout:

https://finance.yahoo.com/news/ventyx-biosciences-announces-results-phase-210100036.html Although the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support advancement of VTX958 in plaque psoriasis. Accordingly, we will terminate ongoing activities in the Phase 2 plaque psoriasis trial effective immediately. Based on these results, we have also elected to terminate the ongoing Phase 2 trial of VTX958 in psoriatic arthritis.

The ongoing Phase 2 trial of VTX958 in Crohn’s disease will continue to enroll and we intend to conduct an interim efficacy analysis in the first quarter of 2024. VTX952 is a TYK2 inhibitor, the same drug class as BMY’s Sotyktu.

VTYX—(-20%/AH)—reports purportedly-positive phase-2 data_in UC:

https://www.globenewswire.com/news-release/2023/10/09/2757021/0/en/Ventyx-Biosciences-Announces-Positive-Results-from-the-Phase-2-Trial-of-VTX002-in-Patients-with-Moderate-to-Severely-Active-Ulcerative-Colitis.html The Phase 2 trial of VTX002 was a 13-week, randomized, double-blind, placebo-controlled, dose-ranging trial evaluating the efficacy and safety of two oral doses of VTX002 (30 mg and 60 mg once daily) in patients with moderate-to-severely active UC. The primary endpoint was the proportion of patients achieving clinical remission at Week 13 as defined by the modified Mayo Clinic Score.

…28% of patients on the 60 mg dose and 24% of patients on the 30 mg dose achieved the primary endpoint of clinical remission at Week 13 compared to 11% of patients on placebo (p=0.018 for 60 mg; p=0.041 for 30 mg). I.e., the absolute effect size was less than some investors apparently expected.

Note: VTX202, an S1P1 modulator, should not be confused with VTX958, a TYK2 inhibitor.

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, announced today that it has entered into a stock purchase agreement for the sale of 5,350,000 shares of its common stock at an offering price of $33.00 per share in a private placement to certain qualified institutional buyers and institutional accredited investors. Gross proceeds of the private placement are expected to be approximately $176.6 million, before deducting placement agent fees and other expenses. The private placement is expected to close on September 20, 2022, subject to the satisfaction of customary closing conditions.
The private placement was led by Redmile Group, with participation by Boxer Capital, Braidwell LP, EcoR1 Capital, Vivo Capital, Great Point Partners, LLC, Adage Capital Management, Logos Capital, Maven Investment Partners US, Driehaus Capital Management, Acuta Capital Partners, CaaS Capital Management, Woodline Partners LP, Walleye Capital and other investors, including two large mutual funds.

Ventyx currently intends to use the net proceeds from the proposed private placement, together with existing cash and cash equivalents, to fund the clinical development of VTX958, VTX002, VTX2735 and VTX3232, the preclinical development of other programs, research activities and working capital and other general corporate purposes. With the proceeds from the private placement, Ventyx expects to extend its cash runway into 2025. This cash estimate is a preliminary estimate and is based on information available to management as of the date of this private placement, and these estimates could change.

VTYX IS A GREAT $$$$$ OPPORTUNITY.

Complex, but GOOD!!!

Ventyx Shares Surge 59% After Bristol Myers Drug Approved Without Black-Box Warning
1:33 pm ET September 12, 2022 (Dow Jones) Print
By Josh Beckerman


Ventyx Biosciences Inc. shares rose 59% to $36.80 after analysts mentioned favorable signs related to the approval of Bristol Myers Squibb Co.'s psoriasis drug Sotyktu.

Stifel, Evercore ISI and Oppenheimer analysts noted that the U.S. Food and Drug Administration approval of the TYK2 inhibitor didn't include a black-box warning.

Jeff Jones and Leland Gershell at Oppenheimer wrote that "we see this as a significant win for deucravacinitib, VTYX and other TYK2 developers, substantially differentiating the TYK2 inhibitors from the JAK 1-3 inhibitors."


Write to Josh Beckerman at josh.beckerman@wsj.com

THANKS!!

Today's pop is due to BMY's FDA approval (#msg-169914579, #msg-169927220).

VTYX: Soaring today???

VTYX reports phase-1 data for VTX858, a potential competitor to BMY’s Deucravacitinib:

https://www.globenewswire.com/news-release/2022/08/15/2498512/0/en/Ventyx-Biosciences-Announces-Positive-Topline-Phase-1-Data-for-Its-Selective-Allosteric-TYK2-Inhibitor-VTX958.html

VTYX plans to start phase-2 trials in psoriasis, psoriatic arthritis, and Crohn’s disease in 4Q22.

The CC this afternoon had a slide set for the phase-1 data, but it hasn’t yet been posted on VTYX’s website.

$VTYX: $125Mlly IPO coming...........


https://ventyxbio.com/


We are a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders.

Our clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.




GO $VTYX